source
- GSK's B7-H3 ADC cuts osteosarcoma progression risk by 67% in Chinese phase 3 trialA phase 3 study in China evaluated GSK's B7-H3‑directed antibody‑drug conjugate, risvutatug rezetecan (ris‑rez), in patients with relapsed osteosarcoma. The trial met its primary endpoint, showing…
- Syntax Bio claims four-day stem-cell conversion into pancreatic beta cellsChicago-based Syntax Bio says its Cellgorithm platform can turn stem cells into pancreatic beta cells in as little as four days. The company describes the process as a programmable set of epigeneti…